trial

Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder

NCTId NCT00113594
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 100
Sponsored by Eli Lilly and Company
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
100
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2005-06
Primary completion
—
Eligibility
ALL · 13 Years · 17 Years

Interventions & indications

Drugs
Olanzapine

Sponsors

Eli Lilly and CompanyLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

17 total
Cerritos, United StatesNational City, United StatesPoway, United StatesFort Lauderdale, United StatesEagle, United StatesLake Charles, United StatesGlen Burnie, United StatesAlbuquerque, United StatesNew York, United StatesOlean, United StatesCincinnati, United StatesHouston, United States

Facts & assertions

3 sourced
Enrollment
100
Phase
PHASE3
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
lead_sponsor
Eli Lilly and Company
company
indication
Schizophrenia
indication
Bipolar Disorder
indication
Bipolar Disorder
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person